IMPORTANCE Waldenström macroglobulinemia (WM), an IgM-associated lymphoplasmacytic lymphoma, has witnessed several practice-altering advances in recent years. With availability of a wider array of therapies, the management strategies have become increasingly complex. Our multidisciplinary team appraised studies published or presented up to December 2015 to provide consensus recommendations for a risk-adapted approach to WM, using a grading system.
CONCLUSIONS AND RELEVANCE Recognizing the paucity of data, we advocate participation in clinical trials, if available, at every stage of WM. Specific indications exist for initiation of therapy. Outside clinical trials, based on the synthesis of available evidence, we recommend bendamustine-rituximab as primary therapy for bulky disease, profound hematologic compromise, or constitutional symptoms attributable to WM. Dexamethasone-rituximabcyclophosphamide is an alternative, particularly for nonbulky WM. Routine rituximab maintenance should be avoided. Plasma exchange should be promptly initiated before cytoreduction for hyperviscosity-related symptoms. Stem cell harvest for future use may be considered in first remission for patients 70 years or younger who are potential candidates for autologous stem cell transplantation. At relapse, retreatment with the original therapy is reasonable in patients with prior durable responses (time to next therapy Ն3 years) and good tolerability to previous regimen. Ibrutinib is efficacious in patients with relapsed or refractory disease harboring MYD88 L265P mutation. In the absence of neuropathy, a bortezomib-rituximab-based option is reasonable for relapsed or refractory disease. In select patients with chemosensitive disease, autologous stem cell transplantation should be considered at first or second relapse. Everolimus and purine analogs are suitable options for refractory or multiply relapsed WM. Our recommendations are periodically updated as new, clinically relevant information emerges.
H erein, the Mayo Clinic Cancer Center Myeloma, Amyloidosis and Dysproteinemia and Lymphoma DiseaseOriented Groups, the multidisciplinary panels of experts with a collective experience of treating hundreds of Waldenström macroglobulinemia (WM) cases, update their evidence-based recommendations for the management of WM. Important advances have led to a broader understanding of the biology of this rare cancer since our initial risk stratification-based approach was published in 2010. 1 Clinical and observational studies published or presented through December 2015 are reviewed to provide consensus recommendations for clinicians as patients with WM are infrequently encountered in practice. The guidelines are formulated using a grading system of evidence and grades of recommendations ( Table 1 ). In the absence of adequate data or a clear superiority vis-à-vis a particular approach, we used expert consensus to formalize recommendations (eAppendix 1 in the Supplement). Waldenström macroglobulinemia, a distinct, low-grade B-cell lymphoproliferative disorder (LPD), was initially chronicled more than 70 years ago in Jan Waldenström's 2 landmark cases, and accounts for 1% to 2% of LPDs. 2 It is predominantly a disease of elderly white men, with an overall age-adjusted incidence of 3.8/million-persons/y. 3 Besides racial disparity, the epidemiologic estimates suggest genetic susceptibility and strong familial aggregation (eAppendix 1 in the Supplement). In the Surveillance, Epidemiology, and End Results data analysis (N = 4304), the median overall survival (OS) was 74 months, with a striking improvement for patients whose disease was diagnosed since 2000 (84 vs 64 months for years prior). 4, 5 
Diagnosis
In practice, it is important to adhere strictly to the diagnostic criteria and to exclude other LPDs before establishing the diagnosis of WM. Central to its diagnosis is the detection of IgM monoclonal protein of any size and at least 10% lymphoplasmacytic lymphoma cells in the marrow (Mayo criteria) (eTable 1 in the Supplement). 1, 6, 7 The immunophenotypic hallmark of lymphocytes is a pan-Bcell profile, with expression of surface IgM, CD19, CD20, CD22, and CD79a antigens. 7 Paired tumor/normal whole-genome sequencing was instrumental in the detection of a highly recurrent somatic mutation (leucine265proline) involving the myeloid differentiation primary response 88 (MYD88) gene in almost all (>90%) patients with WM. 8 Another set of recently discovered nonsense and frameshift somatic mutations affecting CXCR4 are similar to those present in WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome, and are harbored by nearly one-third of patients with WM. 9 Data regarding the prognostic and therapeutic implications of these mutations are beginning to unravel, and require confirmation (eAppendix 2 in the Supplement). [9] [10] [11] [12] A focused history and physical examination (eTable 2 in the Supplement) is required in all patients.
Recommendations
• In cases of suspected, histopathologically difficult-to-interpret lymphoplasmacytic lymphoma, MYD88 mutation status should be assessed by allele-specific polymerase chain reaction assay (level 3, grade A)
Risk Stratification and Response Assessment
Waldenström macroglobulinemia has a heterogeneous disease course. [13] [14] [15] [16] With the median age of 69 years at presentation, and accompanying comorbidities in a substantial proportion of patients, its management can be challenging. The median diseasespecific survival of 10-11 years attests to its indolent course. 14, 17 The
International Prognostic Scoring System was developed through a collaborative analysis of treatment-naive symptomatic patients with WM (eTable 2 in the Supplement). 16 Although used for patient stratification in trials, and externally validated, its value in treatment decision making remains unproven.
• Virtually all patients with symptomatic WM transition from precursor conditions: IgM monoclonal gammopathy of undetermined significance (MGUS) and smoldering WM (SWM). However, SWM (eTable 1 in the Supplement) is infrequently recognized (eAppendix 3 in the Supplement). The temptation to manage an increased size of the monoclonal protein with immediate therapy should be resisted. We endorse the specific indications, developed at the Second International Workshop on WM, to initiate therapy. 18 Acknowledging the paucity of level I evidence, we approach patients by categorizing them into 3 groups (Figure, A) with distinct, risk-adapted strategies, discussed herein. We consistently use the Sixth International Workshop Response Criteria for WM (eTable 3 in the Supplement) for response assessment.
Recommendations
• Patients with IgM MGUS or SWM with preserved marrow function should be managed with a "wait and watch" approach (level 3, grade B) • Patients with IgM MGUS require lifelong active surveillance (history, physical and laboratory tests) with follow-up at 6 months initially, and then annually, if stable. Patients with SWM require lifelong active surveillance, every 4 months for the first 3 years, every Initial Therapy
The overarching goals of therapy for WM are to achieve symptomatic relief and reduce further organ damage without compromising the quality of life. As WM cells of treatment-naive patients uniformly express CD20, rituximab, a generally well-tolerated chimeric anti-CD20 antibody, has become a backbone to which several other agents have been successfully integrated. [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] Rituximab monotherapy is associated with a median progressionfree survival (PFS) of 16 to 29 months, and an overall response rate (ORR) of 25% to 40% from a single 4-week cycle and 65% with an extended course of 2 4-week cycles administered 8 weeks apart. 23, 28 The responses may be delayed (median, 7 months). 28 For patients requiring urgent therapy, rituximab is considered inferior to combination therapies. Ofatumumab, a human anti-CD20 antibody, has been successfully used in patients intolerant to rituximab. 30 Literature, to date, is devoid of comparative trials involving single-agent rituximab, and our riskadapted approach considers its use only in low-risk, symptomatic WM (Figure, A) .
• Rituximab is indicated in WM with symptomatic mild to moderate anemia, symptomatic cryoglobulinemia (in combination with steroids), or hemolytic anemia unresponsive to corticosteroids (level 3, grade B) • Rituximab monotherapy is contraindicated in patients with symptomatic hyperviscosity, and, without preemptive plasmapheresis, is best avoided in patients with very high serum IgM (level 3, grade A) • To avoid underestimation of the magnitude of response to rituximab monotherapy, a lag period to attain maximal response should be taken into account (level 3, grade A) • Because TTNT is often delayed, and the indications of retreatment can emerge ≥12 mo after the detection of biochemical progression, we recommend using a 3-y TTNT cutoff (equivalent of the median PFS of the DRC study) to determine whether the original therapy may be repeated at relapse. In the DRC study, among patients who received second-line treatment, 70% were retreated with a rituximab-based regimen and attained high response rates (82%) • CXCR4 mutations confer a degree of resistance to ibrutinib therapy. However, the efficacy of this agent is primarily determined by the MYD88 mutation status. Patients with the MYD88 mutation alone achieved a metabolic response rate of 92% vs 62% for patients with MYD88 plus CXCR4 mutations, and 0% for the MYD88 WT and CXCR4 WT • BR combination therapy produces an ORR >80% in the salvage setting, and the responses appear to be durable. Neuropathy is a major toxic effect associated with bortezomib therapy • Despite substantial efficacy, the unfavorable toxicity profile of everolimus makes it a difficult-to-use initial salvage therapy • A large European Bone Marrow Transplant Registry experience (N = 615) has demonstrated superior outcomes with early ASCT for patients responding to induction therapy compared with those with refractory disease Abbreviations: AL, immunoglobulin light-chain; ASCT, autologous stem cell transplantation; AS-PCR, allele-specific polymerase chain reaction; BR, bendamustine and rituximab; CLL, chronic lymphocytic leukemia; DRC, dexamethasone-rituximab-cyclophosphamide; HVS, hyperviscosity syndrome; MGUS, monoclonal gammopathy of undetermined significance; MYD88, myeloid differentiation primary response 88; ORR, objective response rate; PFS, progression-free survival; SWM, smoldering WM; TPE, therapeutic plasma exchange; TTNT, time to next therapy; WT, wild type. a After ruling out transformation to a lymphoma of higher histologic grade and other medical conditions that could potentially cause constitutional symptoms.
b Flare, a phenomenon associated with a 25% or greater increase in baseline monoclonal proteins, has the potential to exacerbate IgM-associated morbidity. 19 • In patients with slowly progressing, mild IgM peripheral neuropathy (PN) with otherwise quiescent WM, we recommend conservative therapeutic strategies (level V, grade D) • We recommend a trial of rituximab at 375 mg/m 2 intravenously once weekly for 4 weeks in patients with isolated IgM-related, subacute, progressive disabling sensorimotor PN (eAppendix 4 in the Supplement) with moderate to severe functional impairment (level 2, grade C) Therapeutic plasma exchange facilitates rapid removal of circulating IgM pentamers on an emergent basis and plays an important adjunctive-albeit a temporary-role in ameliorating hyperviscosityrelated symptoms until the cytoreductive therapy effectively decreases the disease burden and, in turn, its surrogate marker, the IgM protein (eAppendix 4 in the Supplement). 31 The schedule and efficacy of a few commonly used regimens in WM are outlined in eTables 4 and 5 in the Supplement.
With the emergence of compelling phase 3 data from the Study Group Indolent Lymphomas (StiL) trial, bendamustine/rituximab (BR) has catapulted to a commonly used frontline regimen with manageable toxicity profile. 26 A subset analysis involving patients with WM (n = 41) compared BR (n = 22 of 261) to rituximab plus cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone (R-CHOP) (n = 19 of 253). While high ORR (approximately 95%) was evident with both regimens, better tolerability (lower rates of infections, hematologic toxic effects, PN, stomatitis, and alopecia) and, importantly, longer PFS (median 69.5 months; interquartile range, 36.6-73.0 months) was notable with BR. 26 However, a clear OS advantage with BR has not yet been demonstrated. In a multicenter, phase 2 trial of 72 treatment-naive patients with WM, dexamethasone-rituximab-cyclophosphamide (DRC) proved to be safe and neuropathy sparing. An ORR of 83%, with low (9%) rates of grade 3 to 4 toxic effects, was noted (eTable 5 in the Supplement). 32 Importantly, therapy-related myelodysplastic syndrome has not been documented so far, and the majority of those requiring retreatment demonstrated a meaningful response (ORR, 82%) to rituximab-based salvage therapy. 33 Given the modest toxicity profile and stem cell-sparing effect, DRC was considered the initial regimen of choice in our guidelines previously. 1 The caveats with the aforementioned regimens are that DRC was evaluated in a single-arm study and the StiL study did not compare BR with the most effective contemporaneous regimens for WM. 26, 32 Furthermore, despite the high ORR, the suitability of R-CHOP as a frontline regimen is questioned, given the concerns of vinca alkaloidassociated neurotoxicity, potential for cardiotoxicity, and inferiority of the CHOP backbone to even older agents such as fludarabine phosphate.
A large phase 3 trial (WM1) has demonstrated superiorityincluding OS advantage-of oral fludarabine to chlorambucil in treatment-naive patients with advanced WM. 34 In contrast to the reports from prior retrospective studies, second cancers were more frequent with chlorambucil therapy (6-year cumulative incidence rate 20.6% vs 3.7% with fludarabine). 34 Notwithstanding the unavailability of oral fludarabine in the United States, and the limited practical applicability of the WM1 trial comparing monotherapies in the era of rituximab-based combinations, this study illustrates that the choice of initial therapy significantly affects OS. Three small phase 2 studies have evaluated bortezomib-based combinations in the frontline setting, showing an ORR of 81% to 96%. 22, 24, 35 Although bortezomib, the first-in-class proteasome inhibitor, elicits rapid (median, 1.4-3 months) and durable responses, an underlying PN at diagnosis, as well as an increased predisposition for PN even with its absence at baseline, raises concern for the use of this neurotoxic agent in patients with WM. In the WMCTG 05-180 trial, a majority developed PN (overall, 69%; grade 3, 30%), resulting in premature discontinuation in 61% of patients. 35 To mitigate the risk of PN the bortezomib-dexamethasone-rituximab regimen was modified, transitioning patients from twice to once weekly intravenous administration of bortezomib beyond the first cycle. 22 Reduced frequency of administration decreased neurotoxic effects (grade 3, 0%-7%) and resultant discontinuation (approximately 8%) but compromised the response (major response rate, 65%-68%). 22, 24 The ongoing R2W trial (NCT01592981), using a potentially less neurotoxic, subcutaneous route for bortezomib, compares bortezomib-containing and fludarabinecyclophosphamide-rituximab regimens, and could help clarify any potential advantages of using rituximab-bortezomib combination over conventional chemoimmunotherapy. Newer proteasome inhibitors (eAppendix 4 in the Supplement) have the potential to overcome some of the bortezomib-associated challenges. Trials assessing the irreversible Bruton tyrosine kinase inhibitor, ibrutinib, in the frontline setting are currently under way (NCT02165397).
A single retrospective study supports the use of rituximab maintenance in WM, but the results of the StiL NHL7-2008 trial addressing this important issue are awaited (eAppendix 4 in the Supplement).
• Therapeutic plasma exchange should be promptly initiated for hyperviscosity syndrome, prior to commencement of cytoreductive therapy (level 3, grade B) • We consider 4 to 6 cycles of BR, with its tolerable toxicity profile and ability to induce durable responses, to be our primary regimen of choice for symptomatic treatment-naive patients with WM, particularly bulky disease when expeditious disease control is desired (level 2, grade B) • Dexamethasone-rituximab-cyclophosphamide may be an alternative in patients with symptomatic WM when the disease burden is low (level 3, grade B). tients with relapsed disease hinge on a multitude of factors, including the magnitude and durability of remission with prior therapy, patients' candidacy for autologous stem cell transplantation (ASCT), the type and number of prior regimens and their tolerability, the patients' preferences, the pace of relapse, the impact on future treatment options, and most importantly, the need to reinitiate therapy. The study involving DRC demonstrated substantially longer time to next therapy (TTNT; median, 51 months) than PFS (median, 36 months), underscoring that biochemical progression does not equate with the requirement to reintroduce therapy. 33 The indications for initiating treatment in relapsing patients are largely similar to those for the treatment-naive patients. Similar to the frontline setting, comparative trials to determine the optimal approach are nonexistent. Retreatment with the initial therapy can be considered if the TTNT is at least 3 years from the commencement of previous therapy (Figure, B) . Bendamustine, as monotherapy and in combination with rituximab and/or ofatumumab, has shown an ORR of 83% in relapsed-refractory WM but leads to prolonged myelosuppression in patients previously exposed to a nucleoside analog. 36, 37 More recently, an Italian retrospective study of patients with relapsed-refractory WM (n = 71) reported an ORR of 80% with BR, with the median PFS not being reached after a median follow-up of 19 months. Transformation or therapy-related myelodysplastic syndrome/acute myeloid leukemia was not observed. 37 The appropriate subset of patients with WM who should be offered ASCT, as well as its optimal timing, is unestablished, with indolent disease course, advanced age, and multiple comorbidities at presentation rendering a large proportion of candidates transplant ineligible. Moreover, its rarity hampers conduction of trials comparing ASCT with alternative approaches.
Despite the lack of data to support survival advantage with myeloablative therapy in WM, several studies have reported encouraging results suggesting long-term disease control with ASCT. 38, 39 In the European Bone Marrow Transplant Registry series (n = 158), the disease chemosensitivity at ASCT affected outcome. The modest nonrelapse mortality rate (3.8%), with estimated 5-year PFS and OS rates of 40% and 69%, respectively, attest to the tolerability and efficacy of ASCT. 39 In patients who are potentially ASCT eligible, particularly those presenting with active disease at age 70 years or younger, consideration should be given to stem cell harvest in first remission after a low tumor burden has been achieved. Without evidence supporting survival benefit, ASCT is best avoided as a primary consolidative approach outside a trial. Our preferred strategy is to use cryopreserved cells early in the relapsed setting in chemosensitive disease because the efficacy of ASCT is markedly reduced in heavily pretreated (Ն3 lines of prior therapy)/refractory WM. Despite graft-vslymphoma effect and high complete response rates (62%-66%), the associated toxic effects and the prohibitively high 1-year treatmentrelated mortality rates of up to 44% limit the use of allogeneic transplantation (eAppendix 4 in the Supplement). 38 A phase 1 trial of advanced B-cell malignant neoplasms demonstrated strong activity of ibrutinib in the WM cohort, 40 prompting a phase 2 study with relapsed-refractory disease (n = 63).
41,42
The convincing results of this trial led to ibrutinib's approval for WM in the United States and the European Union in 2015. Rapid reduction in IgM (median time to response, 1.2 months), in parallel to the hematocrit increase, was evident. While MYD88 L265P-Bruton tyrosine kinase complex promotes cell proliferation and makes cells susceptible to ibrutinib therapy, the presence of CXCR4 WHIM confers resistance. Significant activity (ORR, 95.5%) was noted, with highest response rates witnessed in those harboring MYD88 L265P and CXCR4 wild-type (WT) genotype. 41, 42 Although superior PFS and improved tolerability was noted in the less pretreated patients (as expected), data with ibrutinib for treatment-naive WM are currently unavailable. Importantly, complete responses have not been observed and the follow-up remains short. The estimated 2-year PFS and OS of 69% and 95%, respectively, are comparable to those of other salvage therapies. Notably, IgM-mediated PN improved or stabilized with ibrutinib treatment, and IgM flare was not observed. Clinicians should be mindful of the drug-drug interactions and toxic effects associated with ibrutinib treatment, including neutropenia, thrombocytopenia, postprocedural hemorrhage, epistaxis with concurrent fish oil use, and atrial fibrillation in patients with a history of arrhythmias. Despite these limitations, there is potential to further expand the use of this oral, stem cell-sparing agent as the results of ongoing trials of ibrutinib-based combinations unfold (NCT02165397). 43 The purine analogs cladribine and fludarabine phosphate are effective against relapsed-refractory WM as single agents (ORR, 31%-55%) [44] [45] [46] as well as combination therapies 25, 27, 47 (ORR, 79%-96%; complete response, 12% with fludarabinecyclophosphamide-rituximab and 25% with cladribinerituximab). However, toxic effects, including stem cell toxicity, prolonged myelosuppression/immunosuppression with infections, and secondary malignant neoplasms/transformation have limited their use. 48 The PI3K/AKT/mTOR pathway is another constitutively activated pathway regulating cell metabolism, proliferation, survival, and angiogenesis in WM. 49 Everolimus, an oral mTORC1 inhibitor, 50 can produce responses bearing a striking resemblance to those from ibrutinib treatment, with rapid IgM reduction (median time to response, 2 months; median duration of response, not reached) in the face of persistent marrow infiltration. However, everolimus causes mucositis, diarrhea, fatigue, and dose-dependent myelosuppression.
Recommendations
• With biochemical progression alone, patients can be observed until the reemergence of symptoms, unless there is historical evidence of hyperviscosity syndrome with a prior known symptomatic IgM threshold for an individual patient (level 3, grade B) • The disease burden should be reexamined by imaging and marrow reevaluation (and reassessment of CD20 expression if rituximab integration is contemplated with therapy) prior to initiation of salvage therapy as certain therapies (purine analogs, ibrutinib, everolimus, or bortezomib-based therapies) (eAppendix 4 in the Supplement) demonstrate discordant IgM and marrow responses (level 3, grade B) • Consideration to repeating previous therapy may be given in relapsing patients who had achieved durable responses without substantial toxic effects to prior treatment. Because TTNT is often delayed and can occur 12 or more months after biochemical progression, we recommend using a 3-year TTNT cutoff to determine whether the original therapy may be repeated at relapse (level 3, grade B) • Ibrutinib monotherapy is a viable option for patients with MYD88 mutation (irrespective of CXCR4 mutation) in their first or second relapse. MYD88 mutation status should be assessed prior to ibrutinib use as it is not sufficiently effective in MYD88-WT cases (level 3, grade B)
• A bortezomib-based combination (eg, bortezomib-dexamethasone-rituximab) is a suitable salvage regimen, provided the underlying PN, if present, is grade 2 or less (level 3, grade B) • Autologous stem cell transplantation should be considered for first or second relapse in transplant-eligible patients with chemosensitive disease, especially if the first remission duration is short (<2 years). Patients with refractory WM should not be offered ASCT (level 3, grade B) • Everolimus or purine analogs are considered suitable in select patients with refractory or multiply relapsed disease (level 3, grade B) Table 3 highlights our key differences from other published guidelines.
Future Directions
Substantial recent progress, particularly the seminal discoveries of MYD88 and CXCR4 mutations, has paved the way for an exciting era in WM treatment. Extensive evaluations are ongoing to determine the precise role of these mutations. Furthermore, the therapeutic armamentarium against WM is poised to expand as the efficacy of several new, potentially effective agents, including the secondgeneration BCR inhibitors, oral proteasome inhibitors (ixazomib and oprozomib), B-cell lymphoma 2 inhibitor (venetoclax), glycoengineered anti-CD20 antibody (obinutuzumab), and programmed cell death 1 inhibitors, is being examined. In particular, targeted therapies need to be developed for the MYD88 WT patient population.
We periodically update our evidence-and consensus-driven recommendations at http://www.mSMART.org to present a coherent management approach as new clinically relevant data emerge. Dr The disciplinary diversity of our panel of professionals, with a vast collective experience of managing WM and its complications, has facilitated the development of our mSMART recommendations and consensus statements that differ from existing guidelines in several key aspects. Rather than creating a compendium of alphabetically listed chemotherapeutic regimens for the busy clinicians, who are likely to infrequently encounter this malignancy in their day-to day practice, we provide a few simple, evidence-based, off-study approaches that are our preferred and tested management strategies for the delivery of high-quality care to WM patients in routine practice. We explain, step-by-step, the rationale for our preferences in a variety of clinical scenarios, thereby assisting clinicians in making decisions logically and efficiently from the time of establishment of the diagnosis onwards.
Our criteria for WM and SWM from MGUS (e Table1) are based on the distinctive natural histories of these disorders and continue to be supported by newer studies. Recognizing the paucity of strong comparative data in this rare disease, the pragmatic patient-based mSMART approach that we have espoused is an outcome of an unbiased and careful vetting of the available data, taking into account not only the efficacy of different treatments but weighing the available options against a multitude of factors, including the duration of therapy, associated toxicities and the patient population in which the regimens have been previously evaluated.
Familial WM
A patient s disease is considered familial WM if a first-or a second-degree relative is diagnosed with any lymphoproliferative disorder. Prospective studies have yet to verify the therapeutic advantage of altering an approach on the basis of familial predisposition. A large Swedish population-based study indicates that a first-degree relative of a patient with WM has a 20-fold increased risk of developing WM, and a 3-to 5-fold increased risk of other B-cell lymphoproliferative disorders, including NHL, CLL or MGUS. 1 However, given the relatively low incidence of WM, the absolute risk of a first-degree relative developing a B-cell malignancy remains low. Familial predisposition emerged as an independent marker for disease progression relative to sporadic cases, and was associated with an inferior timeto-progression (TTP) and time-to-next-therapy (TTNT, duration of time from completion or removal from trial to the next therapy), but not OS (not assessable due to few events) in a retrospective study of 135 patients with rituximab-naïve WM, 27% of whom had familial disease. 2 Interestingly, in a subset analysis, bortezomib-based regimens achieved superior response rates compared to non-bortezomib-based regimens with a trend towards longer TTP in the familial WM group suggesting that the therapeutic approach could influence the outcome of such patients. 2 A recent study has however shown that the LPL/WM patients with a family history of any chronic LPD had an increased risk of death compared with sporadic LPL/WM patients (HR = 1.34; 95% CI, 1.03-1.75). An important limitation of this large population-based study was that the patients were not treated with novel agents such as bortezomib which could potentially have favorably impacted the outcome of the familial form. 3 
Diagnosis of WM:
Overt WM should be distinguished from IgM monoclonal gammopathy of undetermined significance (MGUS) prior to formulating a treatment plan. [4] [5] [6] Interestingly, the patients with IgM MGUS -the clonal cells of which are indistinguishable from WM cells-have OS similar to that of the general population, whereas WM patients have a reduced survival. 7, 8 This observation supports the Mayo criteria that unlike other proposed definitions differentiate WM from IgM MGUS on the basis of the degree of marrow involvement rather than the mere presence or absence of clonal marrow infiltration Serum IgM monoclonal protein level >3 g/dL and/or bone marrow lymphoplasmacytic infiltration >10% without evidence of end-organ damage, such as anemia, constitutional symptoms, hyperviscosity, lymphadenopathy, or hepatosplenomegaly, that can be attributed to a lymphoplasmacytic proliferative disorder Serum IgM monoclonal protein level <3 g/dL, bone marrow lymphoplasmacytic infiltration ≤10%, and no evidence of anemia, constitutional symptoms, hyperviscosity, lymphadenopathy, or hepatosplenomegaly.
*In

II. Consensus Panel WM
IgM monoclonal gammopathy with M protein of any size and histologic evidence of bone marrow involvement by lymphoplasmacytic lymphoma.
III. World Health Organization (WHO); WM
A lymphoplasmacytic lymphoma (defined as a neoplasm of small B lymphocytes, plasmacytoid lymphocytes, and plasma cells, usually involving bone marrow and sometimes lymph nodes and spleen, which does not fulfil criteria of any other small B-cell lymphoid neoplasms that may also have plasmacytic differentiation) with bone marrow involvement and an IgM monoclonal gammopathy of any concentration.* cells ranging from small lymphocytes and plasmacytoid lymphocytes to well-formed plasma cells, generally aligned in an intertrabecular pattern. 9 The plasmacytic component, 
Significance of MYD88
MYD88 functions as an adaptor molecule in the toll-like receptor (TLR) signaling pathway and activates a crucial transcription factor, NF-B that in turn promotes growth and survival of WM cells. It is hypothesized that the amino acid substitution of lysine with proline in the MYD88 protein as the result of a recurrent T to C point mutation, serves as an early oncogenic event as underscored by the existence of this mutation in over one-half of IgM MGUS cases. 12, 13 For the detection of this mutation, an allele-specific polymerase chain reaction (AS-PCR) assay is a more sensitive, expedient, cost-effective and reliable alternative to WGS or Sanger sequencing. MYD88 L265P was detected in 93% of WM and 54% The prognostic potential of MYD88 L265P mutation is appreciated even in the precursor condition, IgM MGUS in which the presence of MYD88 L265P appears to increase the risk of progression to WM or another lymphoproliferative disorder independent of the size of M-spike. A high index of suspicion should be maintained for hyperviscosity syndrome (HVS) and concomitant IgM-related disorders including AL amyloidosis, cold agglutinin disease and cryoglobulinemia in order to initiate appropriate work-up. Approximately 10-20% of SWM patients may not require treatment for nearly a decade from diagnosis. 22, 23 Indeed, early institution of therapy in an asymptomatic precursor phase has not been proven to favorably impact OS, and may expose patients to the detriments of toxic therapies. 24, 25 Therefore, the importance of careful determination of the need to commence therapy cannot be overemphasized.
Tests performed at diagnosis of WM
While patients with smoldering WM do not exhibit significant cytopenias or symptoms attributable to WM, and should remain under active surveillance, those with clinically active disease can present with distinctive symptoms. Smoldering WM patients who are followed until progression to active disease, show response rates and survival after institution of treatment for overt disease that appear to be similar to their counterparts who are treated promptly for symptomatic disease from outset. 25 Of 452 patients with WM evaluated at Mayo Clinic, Rochester, 19% had SWM. 5 The cumulative probability of progression to symptomatic WM or a related condition was approximately 12% per year (6% at 1 year, 39% at 3 years and 59% at 5 years) for the first 5 years and then 2% per year for the next 5 years (68% at 10 years). The four significant risk factors for progression included the degree of marrow infiltration, size of the serum monoclonal spike, hemoglobin concentration and the presence of IgA reduction. 5 In the Southwestern Oncology Group (SWOG) trial, S9003, only 12 (21%) of the 59 treatment-naive patients who were initially observed eventually required therapy at a median follow up of 100 months. 23 In contrast, the cumulative risk of progression of IgM MGUS to a symptomatic lymphoproliferative disorder is at a rate of 1.5% per year. The size of serum monoclonal protein and albumin are two independent determinants of the risk of progression. 26 The patients with IgM MGUS, SWM and those without hematologic compromise or with minimal symptoms need to be observed, irrespective of the degree of marrow infiltration. Monoclonal gammopathy-induced hyperviscosity was designated as a category I indication for therapeutic apheresis by the American Society for Apheresis (ASFA) 2013 guidelines. 33 The risk of rituximab-induced flare has also led ASFA to support prophylactic plasma exchange to reduce IgM to <5000mg/dL in preparation for a rituximab-containing therapeutic regimen. 33 IgM reduction may correlate with improvement in symptoms and conversely, therapeutic benefit may be witnessed even without a 50% IgM decline. 28 Due to a nonlinear correlation of serum viscosity with IgM, substantial viscosity reduction is feasible with small-volume plasma exchange (a temporizing measure), and as much as a 30% reduction in viscosity can be achieved per session. 34 The variability of IgM kinetics with different therapies should be factored while assessing response. Therapies such as ibrutinib, bortezomib and everolimus exhibit rapid M-protein responses whereas purine analogs, alkylating agents and rituximab demonstrate a gradual decline in IgM levels.
Peripheral neuropathy in WM
The most common paraproteinemic neuropathy encountered in WM patients is clinically indistinguishable from IgM-MGUS neuropathy. It is generally slowly progressive, distal, symmetrical and sensory-predominant. It leads to unsteadiness (sensory ataxia), and can additionally cause tremor. Nerve conduction studies may demonstrate demyelinating (27% of patients) or axonal (62%) features. 35 Axonal loss is evident both by the electrophysiological findings and on teased nerve fibers, similar to that in IgM-MGUS, which likely accounts for the similar type and severity of impairments. 35 Although approximately 50% of patients with IgM neuropathy have anti-myelin associated glycoprotein (MAG) antibodies, the severity of neuropathy or response to therapy is independent of anti-MAG titer. However, the probability of a link between the IgM paraprotein and the neuropathy is enhanced with the detection of IgM antibodies against MAG. 36 Axonal and autonomic neuropathy associated with concomitant amyloidosis or the direct infiltration of the nerve (peripheral Bing-Neel syndrome) occurs less frequently.
Peripheral neuropathy may be the initial manifestation of cryoglobulinemia usually presenting with a painful, asymmetrical sensory or sensorimotor neuropathy or as mononeuritis multiplex. 37 Subclinical peripheral nerve dysfunction in cryoglobulinemia can be detected on electrodiagnostic studies that typically disclose polyneuropathy, and less commonly, multiple mononeuropathies. Plasma exchange, intravenous immunoglobulins (IVIG), corticosteroids, chemotherapeutic agents, rituximab with or without chemotherapy (purine analogs and/or alkylating agents) combinations have been utilized to treat IgM-peripheral neuropathy with variable efficacy. IVIG was deemed relatively safe in two small trials with 33 participants, with short term benefits but there is no evidence that the effect is sustained 38, 39 Approximately 50-60% of patients with neuropathy appear to respond to rituximab in uncontrolled studies, although a few studies have either reported no benefit or worsening of neuropathy. 40, 41 Moreover, the scales to appropriately capture the primary outcome measures in all patients with IgM neuropathy are inadequate. 42 In an intention-to-treat (ITT) analysis of a small (n=26) rituximab versus placebo controlled randomized trial, improvement was noticeable in the patient clinical assessment and questionnaires at 8 months in 4/13 patients treated with rituximab versus 0/13 receiving placebo. 43 Although, the RIMAG study, a larger, double-blind, placebocontrolled trial of rituximab for IgM anti-MAG neuropathy with a different disabilityinclusion criteria failed to show change in the inflammatory neuropathy cause and treatment (INCAT) sensory score (ISS) at month 12 in an ITT analysis, the per-protocol analysis showed an improvement of points in the INCAT disability scale and the selfevaluation scales. 44 RCTs involving chemoimmunotherapy for the management of IgM neuropathy have not been conducted. Ibrutinib appears to be associated with symptomatic subjective improvement or stability in sensory neuropathy-related symptoms, although it has not been systematically evaluated in patients with progressive IgM-related peripheral neuropathy. 45 
Efficacy of Newer Proteasome inhibitors in WM
The efficacy of carfilzomib, a second generation irreversible PI, has been examined in a single-arm trial of WM patients who were unexposed to a PI or rituximab and had not received more than one line of prior therapy. 32 Herpes zoster prophylaxis is mandatory with regimens containing a PI. Oral PIs, oprozomib and ixazomib, with their favorable neurotoxicity profiles are currently under evaluation in WM.
Efficacy of immunomodulatory drugs (IMiDs) in WM
The limited use of IMiDs in WM stems from their unfavorable toxicity profile: disabling neurotoxicity with thalidomide 46 and significant anemia induced by lenalidomide. 47 Furthermore, a single-arm Mayo Clinic study suggested that ORR (80%) and PFS (median, 25 months) observed with lenalidomide plus DRC are similar to those documented with DRC triplet. infections and other expected toxicities, including hypersensitivity, were notable observations with maintenance. 49 The data from the ongoing StiL NHL 7-2008 trial (NCT00877214), involving treatment-naïve WM patients receiving upto 6 cycles rituximabbendamustine plus 2 cycles of consolidative rituximab followed by the randomization of responders to either rituximab maintenance every 2 months for 2 years or observation, are expected to shed more light on this issue. Abbreviations: TTP, time to progression; y, years; PFS progression-free survival; ORR, Overall response rate; PR, partial response; TN, treatment naïve; TTF time to treatment failure; TN, treatmentnaïve; R/R, relapsed or refractory DRC, dexamethasone, rituximab, and cyclophosphamide, R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; FCR Fludarabine, cyclophosphamide and rituximab, BDR, bortezomib, dexamethasone and rituximab; CaRD, carfilzomib, rituximab, and dexamethasone. NR, not reached
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